Noopept vs PACAP-38
Head-to-head comparison of Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) and PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Noopept | PACAP-38 |
|---|---|---|
| Category | Cognitive Enhancement | Cognitive Enhancement |
| Full Name | N-phenylacetyl-L-prolylglycine ethyl ester | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) |
| Molecular Weight | 318.37 Da | 4534 Da |
| Half-Life | 20-30 minutes | minutes |
| Amino Acids | N/A | 38 aa |
| Typical Dose | 10-30 mg/day | 10-100 µg preclinical range |
| Route | Oral | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 60 | 650 |
| Research Status | Clinical | Pre-clinical |
Noopept Benefits
- ✓memory recall
- ✓learning efficiency
- ✓attention support
- ✓neurotrophic signaling
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
Noopept Dosing
oral research use|10-30 mg per day in human studies|divided or single daily dosing
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
Noopept Side Effects
- ⚠headache
- ⚠irritability
- ⚠sleep disturbance
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
Research Overview
Noopept
Noopept has been reported to increase NGF/BDNF-related signaling and improve performance in tasks involving learning and recall. Evidence includes preclinical studies and small human studies, but the overall literature is still modest compared with mainstream cognitive drugs.
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.